Biostage, Inc.
BSTG · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.86 | -0.22 | 0.26 | 0.24 |
| FCF Yield | -1.50% | -1.21% | 5.89% | 5.97% |
| EV / EBITDA | -29.00 | -35.82 | -88.26 | -29.23 |
| Quality | ||||
| ROIC | -212.87% | -73.92% | -46.06% | -62.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.52 | 0.46 | -1.54 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -24.14% | -122.04% | -2.91% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 0.85 | 3.44 | 1.70 |
| Interest Coverage | -716.67 | -857.50 | 39.59 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 11.19 | 0.69 | 3.21 | 0.62 |
| Cash Conversion Cycle | -96.85 | -1,110.00 | -130.27 | -506.57 |